1. Home
  2. CTNM vs INSG Comparison

CTNM vs INSG Comparison

Compare CTNM & INSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • INSG
  • Stock Information
  • Founded
  • CTNM 2009
  • INSG 1996
  • Country
  • CTNM United States
  • INSG United States
  • Employees
  • CTNM N/A
  • INSG N/A
  • Industry
  • CTNM
  • INSG Telecommunications Equipment
  • Sector
  • CTNM
  • INSG Telecommunications
  • Exchange
  • CTNM Nasdaq
  • INSG Nasdaq
  • Market Cap
  • CTNM 122.9M
  • INSG 110.6M
  • IPO Year
  • CTNM 2024
  • INSG 2000
  • Fundamental
  • Price
  • CTNM $4.76
  • INSG $7.49
  • Analyst Decision
  • CTNM Strong Buy
  • INSG Buy
  • Analyst Count
  • CTNM 4
  • INSG 3
  • Target Price
  • CTNM $22.50
  • INSG $13.00
  • AVG Volume (30 Days)
  • CTNM 128.0K
  • INSG 112.4K
  • Earning Date
  • CTNM 08-12-2025
  • INSG 08-06-2025
  • Dividend Yield
  • CTNM N/A
  • INSG N/A
  • EPS Growth
  • CTNM N/A
  • INSG N/A
  • EPS
  • CTNM N/A
  • INSG 0.31
  • Revenue
  • CTNM N/A
  • INSG $185,412,000.00
  • Revenue This Year
  • CTNM N/A
  • INSG N/A
  • Revenue Next Year
  • CTNM N/A
  • INSG $14.39
  • P/E Ratio
  • CTNM N/A
  • INSG $27.32
  • Revenue Growth
  • CTNM N/A
  • INSG 20.40
  • 52 Week Low
  • CTNM $3.35
  • INSG $6.24
  • 52 Week High
  • CTNM $22.00
  • INSG $20.67
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • INSG 46.67
  • Support Level
  • CTNM N/A
  • INSG $6.95
  • Resistance Level
  • CTNM N/A
  • INSG $7.49
  • Average True Range (ATR)
  • CTNM 0.00
  • INSG 0.35
  • MACD
  • CTNM 0.00
  • INSG 0.01
  • Stochastic Oscillator
  • CTNM 0.00
  • INSG 59.34

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About INSG Inseego Corp.

Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).

Share on Social Networks: